Reviews Aranesp


No reviews yet.

Aranesp Drug Description
Aranesp®
(darbepoetin alfa) For Injection

WARNINGS
INCREASED MORTALITY, SERIOUS CARDIOVASCULAR EVENTS, THROMBOEMBOLIC EVENTS, STROKE and INCREASED RISK OF TUMOR PROGRESSION OR RECURRENCE
Chronic Renal Failure:

In clinical studies, patients experienced greater risks for death, serious
cardiovascular events, and stroke when administered erythropoiesis-stimulating
agents (ESAs) to target hemoglobin levels of 13 g/dL and above.
Individualize dosing to achieve and maintain hemoglobin levels within
the range of 10 to 12 g/dL.

Cancer:

ESAs shortened overall survival and/or increased the risk of tumor
progression or recurrence in some clinical studies in patients with breast,
non-small cell lung, head and neck, lymphoid, and cervical cancers (see
WARNINGS: Table 1).
To decrease these risks, as well as the risk of serious cardio- and thrombovascular
events, use the lowest dose needed to avoid red blood cell transfusion.
Because of these risks, prescribers and hospitals must enroll in and
comply with the ESA APPRISE Oncology Program to prescribe and/or dispense
Aranesp® to patients with cancer. To enroll in the ESA APPRISE Oncology
Program, visit www.esa-apprise.com or call 1-866-284-8089 for further assistance.

Use ESAs only for treatment of anemia due to concomitant myelosuppressive
chemotherapy.
ESAs are not indicated for patients receiving myelosuppressive therapy
when the anticipated outcome is cure.
Discontinue following the completion of a chemotherapy course.

(See WARNINGS: Increased Mortality, Serious
Cardiovascular Events, Thromboembolic Events, and Stroke, WARNINGS:
Increased Mortality and/or Increased Risk of Tumor Progression or Recurrence,
INDICATIONS AND USAGE, and DOSAGE
AND ADMINISTRATION.)


DRUG DESCRIPTION



What are the possible side effects of darbepoetin alfa (Aranesp, Aranesp Albumin Free, Aranesp SureClick)?

Contact your doctor if you feel weak, light-headed, or short of breath, or if your skin looks pale. These may be signs that your body has stopped responding to darbepoetin alfa.
Darbepoetin alfa can increase your risk of life-threatening heart or circulation problems, including heart attack or stroke. This risk will increase the longer you use darbepoetin alfa. Seek emergency medical help if you have symptoms of heart or circulation problems, such as:

...
Read All Potential Side Effects for Aranesp »




Aranesp® is an erythropoiesis stimulating protein, closely related to erythropoietin,
that is produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology.
Aranesp® is a 165-amino acid protein that differs from recombinant human
erythropoietin in containing 5 N-linked oligosaccharide chains, whereas recombinant
human erythropoietin contains 3 chains.1 The two additional N-glycosylation
sites result from amino acid substitutions in the erythropoietin peptide backbone.
The additional carbohydrate chains increase the approximate molecular weight
of the glycoprotein from 30,000 to 37,000 daltons. Aranesp® is formulated
as a sterile, colorless, preservative-free protein solution for intravenous
or subcutaneous administration.
Single-dose vials are available containing 25, 40, 60, 100, 150, 200,
300, or 500 mcg of Aranesp®.
Single-dose prefilled syringes and prefilled SureClick™ autoinjectors
are available containing 25, 40, 60, 100, 150, 200, 300, or 500 mcg of Aranesp®.
Each prefilled syringe is equipped with a needle guard that covers the needle
during disposal.
Single-dose vials, prefilled syringes and autoinjectors are available in two
formulations that contain excipients as follows:

Polysorbate solution Each 1 mL contains 0.05 mg polysorbate 80, and
is formulated at pH 6.2 ± 0.2 with 2.12 mg sodium phosphate monobasic
monohydrate, 0.66 mg sodium phosphate dibasic anhydrous, and 8.18 mg sodium
chloride in Water for Injection, USP (to 1 mL).
Albumin solution Each 1 mL contains 2.5 mg albumin (human), and is
formulated at pH 6.0 ± 0.3 with 2.23 mg sodium phosphate monobasic
monohydrate, 0.53 mg sodium phosphate dibasic anhydrous, and 8.18 mg sodium
chloride in Water for Injection, USP (to 1 mL).

1. Egrie JC, Browne JK. Development and characterization of
novel erythropoiesis stimulating protein (NESP). Br J Cancer. 2001; 84 (suppl
1): 3-10.
Last reviewed on RxList: 2/25/2010




Aranesp Drug Description
Aranesp®
(darbepoetin alfa) For Injection

WARNINGS
INCREASED MORTALITY, SERIOUS CARDIOVASCULAR EVENTS, THROMBOEMBOLIC EVENTS, STROKE and INCREASED RISK OF TUMOR PROGRESSION OR RECURRENCE
Chronic Renal Failure:

In clinical studies, patients experienced greater risks for death, serious
cardiovascular events, and stroke when administered erythropoiesis-stimulating
agents (ESAs) to target hemoglobin levels of 13 g/dL and above.
Individualize dosing to achieve and maintain hemoglobin levels within
the range of 10 to 12 g/dL.

Cancer:

ESAs shortened overall survival and/or increased the risk of tumor
progression or recurrence in some clinical studies in patients with breast,
non-small cell lung, head and neck, lymphoid, and cervical cancers (see
WARNINGS: Table 1).
To decrease these risks, as well as the risk of serious cardio- and thrombovascular
events, use the lowest dose needed to avoid red blood cell transfusion.
Because of these risks, prescribers and hospitals must enroll in and
comply with the ESA APPRISE Oncology Program to prescribe and/or dispense
Aranesp® to patients with cancer. To enroll in the ESA APPRISE Oncology
Program, visit www.esa-apprise.com or call 1-866-284-8089 for further assistance.

Use ESAs only for treatment of anemia due to concomitant myelosuppressive
chemotherapy.
ESAs are not indicated for patients receiving myelosuppressive therapy
when the anticipated outcome is cure.
Discontinue following the completion of a chemotherapy course.

(See WARNINGS: Increased Mortality, Serious
Cardiovascular Events, Thromboembolic Events, and Stroke, WARNINGS:
Increased Mortality and/or Increased Risk of Tumor Progression or Recurrence,
INDICATIONS AND USAGE, and DOSAGE
AND ADMINISTRATION.)


DRUG DESCRIPTION



What are the possible side effects of darbepoetin alfa (Aranesp, Aranesp Albumin Free, Aranesp SureClick)?

Contact your doctor if you feel weak, light-headed, or short of breath, or if your skin looks pale. These may be signs that your body has stopped responding to darbepoetin alfa.
Darbepoetin alfa can increase your risk of life-threatening heart or circulation problems, including heart attack or stroke. This risk will increase the longer you use darbepoetin alfa. Seek emergency medical help if you have symptoms of heart or circulation problems, such as:

...
Read All Potential Side Effects for Aranesp »




Aranesp® is an erythropoiesis stimulating protein, closely related to erythropoietin,
that is produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology.
Aranesp® is a 165-amino acid protein that differs from recombinant human
erythropoietin in containing 5 N-linked oligosaccharide chains, whereas recombinant
human erythropoietin contains 3 chains.1 The two additional N-glycosylation
sites result from amino acid substitutions in the erythropoietin peptide backbone.
The additional carbohydrate chains increase the approximate molecular weight
of the glycoprotein from 30,000 to 37,000 daltons. Aranesp® is formulated
as a sterile, colorless, preservative-free protein solution for intravenous
or subcutaneous administration.
Single-dose vials are available containing 25, 40, 60, 100, 150, 200,
300, or 500 mcg of Aranesp®.
Single-dose prefilled syringes and prefilled SureClick™ autoinjectors
are available containing 25, 40, 60, 100, 150, 200, 300, or 500 mcg of Aranesp®.
Each prefilled syringe is equipped with a needle guard that covers the needle
during disposal.
Single-dose vials, prefilled syringes and autoinjectors are available in two
formulations that contain excipients as follows:

Polysorbate solution Each 1 mL contains 0.05 mg polysorbate 80, and
is formulated at pH 6.2 ± 0.2 with 2.12 mg sodium phosphate monobasic
monohydrate, 0.66 mg sodium phosphate dibasic anhydrous, and 8.18 mg sodium
chloride in Water for Injection, USP (to 1 mL).
Albumin solution Each 1 mL contains 2.5 mg albumin (human), and is
formulated at pH 6.0 ± 0.3 with 2.23 mg sodium phosphate monobasic
monohydrate, 0.53 mg sodium phosphate dibasic anhydrous, and 8.18 mg sodium
chloride in Water for Injection, USP (to 1 mL).

1. Egrie JC, Browne JK. Development and characterization of
novel erythropoiesis stimulating protein (NESP). Br J Cancer. 2001; 84 (suppl
1): 3-10.
Last reviewed on RxList: 2/25/2010




Aranesp Drug Description
Aranesp®
(darbepoetin alfa) For Injection

WARNINGS
INCREASED MORTALITY, SERIOUS CARDIOVASCULAR EVENTS, THROMBOEMBOLIC EVENTS, STROKE and INCREASED RISK OF TUMOR PROGRESSION OR RECURRENCE
Chronic Renal Failure:

In clinical studies, patients experienced greater risks for death, serious
cardiovascular events, and stroke when administered erythropoiesis-stimulating
agents (ESAs) to target hemoglobin levels of 13 g/dL and above.
Individualize dosing to achieve and maintain hemoglobin levels within
the range of 10 to 12 g/dL.

Cancer:

ESAs shortened overall survival and/or increased the risk of tumor
progression or recurrence in some clinical studies in patients with breast,
non-small cell lung, head and neck, lymphoid, and cervical cancers (see
WARNINGS: Table 1).
To decrease these risks, as well as the risk of serious cardio- and thrombovascular
events, use the lowest dose needed to avoid red blood cell transfusion.
Because of these risks, prescribers and hospitals must enroll in and
comply with the ESA APPRISE Oncology Program to prescribe and/or dispense
Aranesp® to patients with cancer. To enroll in the ESA APPRISE Oncology
Program, visit www.esa-apprise.com or call 1-866-284-8089 for further assistance.

Use ESAs only for treatment of anemia due to concomitant myelosuppressive
chemotherapy.
ESAs are not indicated for patients receiving myelosuppressive therapy
when the anticipated outcome is cure.
Discontinue following the completion of a chemotherapy course.

(See WARNINGS: Increased Mortality, Serious
Cardiovascular Events, Thromboembolic Events, and Stroke, WARNINGS:
Increased Mortality and/or Increased Risk of Tumor Progression or Recurrence,
INDICATIONS AND USAGE, and DOSAGE
AND ADMINISTRATION.)


DRUG DESCRIPTION



What are the possible side effects of darbepoetin alfa (Aranesp, Aranesp Albumin Free, Aranesp SureClick)?

Contact your doctor if you feel weak, light-headed, or short of breath, or if your skin looks pale. These may be signs that your body has stopped responding to darbepoetin alfa.
Darbepoetin alfa can increase your risk of life-threatening heart or circulation problems, including heart attack or stroke. This risk will increase the longer you use darbepoetin alfa. Seek emergency medical help if you have symptoms of heart or circulation problems, such as:

...
Read All Potential Side Effects for Aranesp »




Aranesp® is an erythropoiesis stimulating protein, closely related to erythropoietin,
that is produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology.
Aranesp® is a 165-amino acid protein that differs from recombinant human
erythropoietin in containing 5 N-linked oligosaccharide chains, whereas recombinant
human erythropoietin contains 3 chains.1 The two additional N-glycosylation
sites result from amino acid substitutions in the erythropoietin peptide backbone.
The additional carbohydrate chains increase the approximate molecular weight
of the glycoprotein from 30,000 to 37,000 daltons. Aranesp® is formulated
as a sterile, colorless, preservative-free protein solution for intravenous
or subcutaneous administration.
Single-dose vials are available containing 25, 40, 60, 100, 150, 200,
300, or 500 mcg of Aranesp®.
Single-dose prefilled syringes and prefilled SureClick™ autoinjectors
are available containing 25, 40, 60, 100, 150, 200, 300, or 500 mcg of Aranesp®.
Each prefilled syringe is equipped with a needle guard that covers the needle
during disposal.
Single-dose vials, prefilled syringes and autoinjectors are available in two
formulations that contain excipients as follows:

Polysorbate solution Each 1 mL contains 0.05 mg polysorbate 80, and
is formulated at pH 6.2 ± 0.2 with 2.12 mg sodium phosphate monobasic
monohydrate, 0.66 mg sodium phosphate dibasic anhydrous, and 8.18 mg sodium
chloride in Water for Injection, USP (to 1 mL).
Albumin solution Each 1 mL contains 2.5 mg albumin (human), and is
formulated at pH 6.0 ± 0.3 with 2.23 mg sodium phosphate monobasic
monohydrate, 0.53 mg sodium phosphate dibasic anhydrous, and 8.18 mg sodium
chloride in Water for Injection, USP (to 1 mL).

1. Egrie JC, Browne JK. Development and characterization of
novel erythropoiesis stimulating protein (NESP). Br J Cancer. 2001; 84 (suppl
1): 3-10.
Last reviewed on RxList: 2/25/2010




Aranesp Drug Description
Aranesp®
(darbepoetin alfa) For Injection

WARNINGS
INCREASED MORTALITY, SERIOUS CARDIOVASCULAR EVENTS, THROMBOEMBOLIC EVENTS, STROKE and INCREASED RISK OF TUMOR PROGRESSION OR RECURRENCE
Chronic Renal Failure:

In clinical studies, patients experienced greater risks for death, serious
cardiovascular events, and stroke when administered erythropoiesis-stimulating
agents (ESAs) to target hemoglobin levels of 13 g/dL and above.
Individualize dosing to achieve and maintain hemoglobin levels within
the range of 10 to 12 g/dL.

Cancer:

ESAs shortened overall survival and/or increased the risk of tumor
progression or recurrence in some clinical studies in patients with breast,
non-small cell lung, head and neck, lymphoid, and cervical cancers (see
WARNINGS: Table 1).
To decrease these risks, as well as the risk of serious cardio- and thrombovascular
events, use the lowest dose needed to avoid red blood cell transfusion.
Because of these risks, prescribers and hospitals must enroll in and
comply with the ESA APPRISE Oncology Program to prescribe and/or dispense
Aranesp® to patients with cancer. To enroll in the ESA APPRISE Oncology
Program, visit www.esa-apprise.com or call 1-866-284-8089 for further assistance.

Use ESAs only for treatment of anemia due to concomitant myelosuppressive
chemotherapy.
ESAs are not indicated for patients receiving myelosuppressive therapy
when the anticipated outcome is cure.
Discontinue following the completion of a chemotherapy course.

(See WARNINGS: Increased Mortality, Serious
Cardiovascular Events, Thromboembolic Events, and Stroke, WARNINGS:
Increased Mortality and/or Increased Risk of Tumor Progression or Recurrence,
INDICATIONS AND USAGE, and DOSAGE
AND ADMINISTRATION.)


DRUG DESCRIPTION



What are the possible side effects of darbepoetin alfa (Aranesp, Aranesp Albumin Free, Aranesp SureClick)?

Contact your doctor if you feel weak, light-headed, or short of breath, or if your skin looks pale. These may be signs that your body has stopped responding to darbepoetin alfa.
Darbepoetin alfa can increase your risk of life-threatening heart or circulation problems, including heart attack or stroke. This risk will increase the longer you use darbepoetin alfa. Seek emergency medical help if you have symptoms of heart or circulation problems, such as:

...
Read All Potential Side Effects for Aranesp »




Aranesp® is an erythropoiesis stimulating protein, closely related to erythropoietin,
that is produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology.
Aranesp® is a 165-amino acid protein that differs from recombinant human
erythropoietin in containing 5 N-linked oligosaccharide chains, whereas recombinant
human erythropoietin contains 3 chains.1 The two additional N-glycosylation
sites result from amino acid substitutions in the erythropoietin peptide backbone.
The additional carbohydrate chains increase the approximate molecular weight
of the glycoprotein from 30,000 to 37,000 daltons. Aranesp® is formulated
as a sterile, colorless, preservative-free protein solution for intravenous
or subcutaneous administration.
Single-dose vials are available containing 25, 40, 60, 100, 150, 200,
300, or 500 mcg of Aranesp®.
Single-dose prefilled syringes and prefilled SureClick™ autoinjectors
are available containing 25, 40, 60, 100, 150, 200, 300, or 500 mcg of Aranesp®.
Each prefilled syringe is equipped with a needle guard that covers the needle
during disposal.
Single-dose vials, prefilled syringes and autoinjectors are available in two
formulations that contain excipients as follows:

Polysorbate solution Each 1 mL contains 0.05 mg polysorbate 80, and
is formulated at pH 6.2 ± 0.2 with 2.12 mg sodium phosphate monobasic
monohydrate, 0.66 mg sodium phosphate dibasic anhydrous, and 8.18 mg sodium
chloride in Water for Injection, USP (to 1 mL).
Albumin solution Each 1 mL contains 2.5 mg albumin (human), and is
formulated at pH 6.0 ± 0.3 with 2.23 mg sodium phosphate monobasic
monohydrate, 0.53 mg sodium phosphate dibasic anhydrous, and 8.18 mg sodium
chloride in Water for Injection, USP (to 1 mL).

1. Egrie JC, Browne JK. Development and characterization of
novel erythropoiesis stimulating protein (NESP). Br J Cancer. 2001; 84 (suppl
1): 3-10.
Last reviewed on RxList: 2/25/2010




Aranesp Drug Description
Aranesp®
(darbepoetin alfa) For Injection

WARNINGS
INCREASED MORTALITY, SERIOUS CARDIOVASCULAR EVENTS, THROMBOEMBOLIC EVENTS, STROKE and INCREASED RISK OF TUMOR PROGRESSION OR RECURRENCE
Chronic Renal Failure:

In clinical studies, patients experienced greater risks for death, serious
cardiovascular events, and stroke when administered erythropoiesis-stimulating
agents (ESAs) to target hemoglobin levels of 13 g/dL and above.
Individualize dosing to achieve and maintain hemoglobin levels within
the range of 10 to 12 g/dL.

Cancer:

ESAs shortened overall survival and/or increased the risk of tumor
progression or recurrence in some clinical studies in patients with breast,
non-small cell lung, head and neck, lymphoid, and cervical cancers (see
WARNINGS: Table 1).
To decrease these risks, as well as the risk of serious cardio- and thrombovascular
events, use the lowest dose needed to avoid red blood cell transfusion.
Because of these risks, prescribers and hospitals must enroll in and
comply with the ESA APPRISE Oncology Program to prescribe and/or dispense
Aranesp® to patients with cancer. To enroll in the ESA APPRISE Oncology
Program, visit www.esa-apprise.com or call 1-866-284-8089 for further assistance.

Use ESAs only for treatment of anemia due to concomitant myelosuppressive
chemotherapy.
ESAs are not indicated for patients receiving myelosuppressive therapy
when the anticipated outcome is cure.
Discontinue following the completion of a chemotherapy course.

(See WARNINGS: Increased Mortality, Serious
Cardiovascular Events, Thromboembolic Events, and Stroke, WARNINGS:
Increased Mortality and/or Increased Risk of Tumor Progression or Recurrence,
INDICATIONS AND USAGE, and DOSAGE
AND ADMINISTRATION.)


DRUG DESCRIPTION



What are the possible side effects of darbepoetin alfa (Aranesp, Aranesp Albumin Free, Aranesp SureClick)?

Contact your doctor if you feel weak, light-headed, or short of breath, or if your skin looks pale. These may be signs that your body has stopped responding to darbepoetin alfa.
Darbepoetin alfa can increase your risk of life-threatening heart or circulation problems, including heart attack or stroke. This risk will increase the longer you use darbepoetin alfa. Seek emergency medical help if you have symptoms of heart or circulation problems, such as:

...
Read All Potential Side Effects for Aranesp »




Aranesp® is an erythropoiesis stimulating protein, closely related to erythropoietin,
that is produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology.
Aranesp® is a 165-amino acid protein that differs from recombinant human
erythropoietin in containing 5 N-linked oligosaccharide chains, whereas recombinant
human erythropoietin contains 3 chains.1 The two additional N-glycosylation
sites result from amino acid substitutions in the erythropoietin peptide backbone.
The additional carbohydrate chains increase the approximate molecular weight
of the glycoprotein from 30,000 to 37,000 daltons. Aranesp® is formulated
as a sterile, colorless, preservative-free protein solution for intravenous
or subcutaneous administration.
Single-dose vials are available containing 25, 40, 60, 100, 150, 200,
300, or 500 mcg of Aranesp®.
Single-dose prefilled syringes and prefilled SureClick™ autoinjectors
are available containing 25, 40, 60, 100, 150, 200, 300, or 500 mcg of Aranesp®.
Each prefilled syringe is equipped with a needle guard that covers the needle
during disposal.
Single-dose vials, prefilled syringes and autoinjectors are available in two
formulations that contain excipients as follows:

Polysorbate solution Each 1 mL contains 0.05 mg polysorbate 80, and
is formulated at pH 6.2 ± 0.2 with 2.12 mg sodium phosphate monobasic
monohydrate, 0.66 mg sodium phosphate dibasic anhydrous, and 8.18 mg sodium
chloride in Water for Injection, USP (to 1 mL).
Albumin solution Each 1 mL contains 2.5 mg albumin (human), and is
formulated at pH 6.0 ± 0.3 with 2.23 mg sodium phosphate monobasic
monohydrate, 0.53 mg sodium phosphate dibasic anhydrous, and 8.18 mg sodium
chloride in Water for Injection, USP (to 1 mL).

1. Egrie JC, Browne JK. Development and characterization of
novel erythropoiesis stimulating protein (NESP). Br J Cancer. 2001; 84 (suppl
1): 3-10.
Last reviewed on RxList: 2/25/2010





Other reviews about Aranesp on wordpress

Amgen Dependence on Aranesp Off-Label Use Greatly Exaggerated
  by Chad Brand
I touched on the issues Amgen (AMGN) is having with Aranesp a couple months back, but I decided to take a closer look at the numbers after the […]


Amgen Dependance on Aranesp Off-Label Use Greatly Exaggerated
  by 247wallst
By Chad Brand of Peridot Capitalist I touched on the issues Amgen (AMGN) is having with Aranesp a couple months back, but I decided to take a closer look […]


In the Face of Adversity, Amgen Buys Ilypsa to Bulk Up Product Pipeline
  by Chad Brand
It has been a tough year for Amgen (AMGN) but the world's largest biotechnology company is not standing still while its anemia drug franchise is under attack. After […]


Amgen: Today's Review Critical For Anemia Reimbursements (AMGN)
  by 247wallst
Amgen (NASDAQ:AMGN) has a huge day ahead of it.  The biotech giant is presenting data today on the appropriateuse of Erythropoiesis Stimulating Agents in Chronic RenalFailure patients to […]


Erythropoiesis Stimulating Agents: Aranesp (darbepoetin alfa), Epogen (epoetin alfa), and Procrit (epoetin alfa)
  by Law Offices of Sadaka Associates
FDA informed healthcare professionals of findings from two additional clinical studies, Preoperative Epirubicin Paclitaxel Aranesp Study (PREPARE), and the National Cancer Institute Gynecologic Oncology Group (COG-19), showing an […]


Aranesp may agent hematoscopy assembly lead in contemplation of RBC aplasia and tabes
  by emilivelinus
Darbepoetin (Aranesp) is ordinarily confirmed headed for patients by use of weariness referring to perpetual syndrome(e.chiliagon. thanks to ESRD) in transit to wake up RBC score. […]


Aranesp may agent hematoscopy assembly lead in contemplation of RBC aplasia and tabes
  by emilivelinus
Darbepoetin (Aranesp) is ordinarily confirmed headed for patients by use of weariness referring to perpetual syndrome(e.chiliagon. thanks to ESRD) in transit to wake up RBC score. […]


Halloween to arrive early this year with presentation of TREAT
  by Larry Husten
Trick or Treat? On Friday night, only hours before Halloween, the much-anticipated TREAT (Trial to Reduce Cardiovascular Events with Aranesp Therapy) will be presented by Marc Pfeffer as […]


Considerable stroke risk linked to anemia drug; Darbepoetin-╬▒ [Aranesp] nearly doubled risk in people with diabetes
  by thassodotcom
November 1, 2009 - A new study raises fresh safety concerns about widely used anemia medicines, finding that the drug Darbepoetin-╬▒ [Aranesp] nearly doubled the risk of stroke […]


Avandia, Meridia... now it's Aranesp's turn before the FDA
  by Larry Husten
The FDA Death Panel Cardiovascular and Renal Drugs Advisory Committee will consider the fate of darbepoetin alfa (Aranesp) on October 18. Having failed to impose the death penalty […]



Other reviews about Aranesp on web:

Manufacturer provides indications, side effects, contraindications and mechanisms of action of this treatment for anemia associated with chronic renal failure and chemotherapy. Aranesp®(darbepoetin alfa)


Aranesp (darbepoetin alfa) is used to treat anemia - a lack of red blood cells in the body. Includes Aranesp side effects, interactions and indications. Aranesp Information from Drugs.com


Learn about the prescription medication Aranesp (Darbepoetin Alfa), drug uses, dosage, side effects, drug interactions, warnings, reviews and patient labeling. Aranesp (Darbepoetin Alfa) Drug Information: Uses, Side Effects ...


The DAHANCA 10 data monitoring committee found that 3-year loco-regional control in subjects treated with Aranesp was significantly worse than for those not receiving Aranesp (p=0 ... Darbepoetin alfa - Wikipedia, the free encyclopedia


Indication: Aranesp ® is indicated for the treatment of anemia associated with chronic renal failure (CRF), including patients on dialysis and patients not on dialysis. Aranesp®—A Treatment to fit Your Needs


All about Aranesp. View complete and up to date Aranesp information - part of the Drugs.com trusted medication database. Aranesp Facts and Comparisons at Drugs.com


Aranesp is a medicine that can be prescribed to treat anemia due to chronic kidney failure or chemotherapy. This eMedTV resource describes the effects of Aranesp, explains how and ... Aranesp


Aranesp Drug info from the Consumer Injury Lawyers. Aranesp belongs to a class of drugs known as erythropoiesis-stimulating agents, or ESAs, and is used to treat anemia in ... Aranesp Dangerous Drug - Consumer Injury Lawyers


Because of these risks, prescribers and hospitals must enroll in and comply with the ESA APPRISE Oncology Program to prescribe and/or dispense Aranesp® (darbepoetin alfa) to ... Amgen - Amgen Assist - Reimbursement Services


Parker & Waichman - Personal Injury Lawyers ... Date of birth (mm-dd-yyyy): Date you started taking the drug (mm-yyyy): Date you stopped taking the drug (mm-yyyy): Aranesp Blood Clot Side Effect Injury Attorney





Featured Reviews

Reviews Dexilant

Dexilant Drug Description Dexilant (formerly Kapidex) (dexlansoprazole) Delayed Release Capsules DRUG DESCRIPTION The active ingredient in DEXILANT (dexlansoprazole) delayed release capsules is (+)-2-[(R)-{[3-methyl-4-(2,2,2-trifluoroethoxy)pyri...
Read More  |  Review This
Reviews Fastin

Fastin Drug Description Fastin (phentermine hydrochloride) Capsule DRUG DESCRIPTION Each phentermine hydrochloride capsule contains phentermine hydrochloride, 30 mg (equivalent to 24 mg Phentermine). Phentermine Hydrochloride is a white...
Read More  |  Review This
Reviews Simcor

Simcor Drug Description Simcor (simvastatin/niacin extended-release) Tablet, Film Coated, Extended Release for Oral use DRUG DESCRIPTION What are the possible side effects of niacin and simvastatin (Simcor)? Get emergency medical...
Read More  |  Review This
Reviews Meprobamate

Meprobamate Drug Description Meprobamate Tablets USP DRUG DESCRIPTION What are the possible side effects of meprobamate (Equanil, Miltown)? If you experience any of the following serious side effects, stop taking meprobamate and...
Read More  |  Review This
Reviews Testosterone Cypionate Injection

Depo-Testosterone Drug Description Depo® -Testosterone (testosterone cypionate) Injection, USP DRUG DESCRIPTION What are the possible side effects of testosterone injection? Get emergency medical help if you have any of these...
Read More  |  Review This
Recent News
59sec - the BEST lead management system around!
We tested 59sec - THE lead management system and we love it. 59sec helps small and medium companies to answer leads in maximum 59 seconds. Why...
MOVEorPAY - our favorite facebook app
We do love MOVEorPAY motivational facebook app, because it is very cool and useful. It makes you finish stuff that you know are good for you, but from various reasons, you never do...
ReviewsAZ is almost ready to be officially launched
yes, we have just a few loose ends to tie and we are ready to go :) meanwhile, I am putting some reviews on the site, so people will not get an empty site at the launch....